Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$73.22 USD

73.22
407,321

-0.74 (-1.00%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $73.21 -0.01 (-0.01%) 7:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Fresenius Medical Launches 4008A Dialysis Machine in China

by Zacks Equity Research

Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.

PRA Health Simplifies Treatment Decisions With Metys Launch

by Zacks Equity Research

PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.

Here's Why You Should Retain Pacific Biosciences For Now

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.

Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome

by Zacks Equity Research

Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.

HMS Holdings Acquires VitreosHealth, Boosts PHM Solution Set

by Zacks Equity Research

HMS Holdings (HMSY) can leverage VitreosHealth's prescriptive health insights that will enhance its growing and lucrative PHM suite.

Here's Why You Should Retain OPKO Health (OPK) Stock For Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.

Here's Why You Should Retain Patterson Companies (PDCO) Now

by Zacks Equity Research

Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts. However, intense competition remains a woe.

XRAY vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to Ecolab (ECL) Stock Now

by Zacks Equity Research

Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.

Here's Why You Should Invest in Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base.

Masimo (MASI) Boosts O3 Platform With Three New Indices

by Zacks Equity Research

Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.

Aurora Cannabis (ACB) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Cannabis revenue growth and improved gross margin are likely to aid Aurora Cannabis (ACB) in Q4 earnings.

Here's Why You Should Retain NextGen Healthcare Stock Now

by Zacks Equity Research

NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.

Here's Why You Should Invest in Integer Holdings (ITGR) Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.

What's in Store for Aurora Cannabis (ACB) in Q4 Earnings?

by Zacks Equity Research

Aurora Cannabis (ACB) expects revenues within $100-$107 million in fiscal Q4.

Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring

by Zacks Equity Research

Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.

Here's Why You Should Hold on to DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.

Here's Why You Should Consider Betting on CONMED Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

What's in the Cards for HealthEquity (HQY) in Q2 Earnings?

by Zacks Equity Research

Higher revenues and possible margin expansion are likely to aid HealthEquity (HQY) in Q2 earnings.

Patterson Companies (PDCO) Earnings Beat Estimates in Q1

by Zacks Equity Research

Patterson Companies' (PDCO) Q1 results benefit from higher revenues, gross margin expansion, solid show by Corporate segment and lower expenses.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Ecolab (ECL) Expands Product Portfolio With New Technology

by Zacks Equity Research

Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.

Here's Why You Should Hold on to Cardinal Health (CAH) Stock

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.